AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva

AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4